Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have a platelet, bleeding, or white blood cell disorder? This study is looking at people who have platelet or other blood disorders. The researchers will use a blood sample to look for problems with platelets and a possible genetic cause in the participant’s DNA or RNA. To participate in this study, you must be a child or adult who either is healthy or has a platelet disorder, coagulation disorder, or white blood cell disorder. This study is located in New York, New York.

Are you at least 18 years old and have been told by your doctor that you need a procedure called transcatheter aortic valve replacement? This study will test a new device designed specifically for use during a procedure called transcatheter aortic valve replacement. Researchers want to make transcatheter aortic valve replacement safer. To be in the study, you must be at least 18 and need a transcatheter aortic valve replacement. The study will take place in locations in California, Georgia, Massachusetts, New York, Virginia, Washington, and Washington, D.C.